The markets opened flat with the Dow easing a point to 20,069 over concerns that isolationist policies will hurt the economy. Nasdaq slipped 7 points to 5,659.
On the upside
The Data Safety Monitoring Board for two clinical trials of Galena Biopharma's (Nasdaq: GALE) breast cancer treatment NeuVax found no safety concerns with either trial.
JPMorgan upgraded Cabot Oil & Gas (NYSE: COG) from a Neutral rating to an Overweight rating.
Hasbro (Nasdaq: HAS) impressed with higher fourth quarter earnings and revenue that beat analyst expectations.
On the downside
comScore (Nasdaq: SCOR) will be unable to complete its financial restatements by Nasdaq's deadline and may be delisted.
Aratana Therapeutics (Nasdaq: PETX) must provide additional information to the Center for Veterinary Medicine for its appetite stimulation medication Entyce.
LGI Homes (Nasdaq: LGIH) reported sharply lower home closings in January.
In the broad market, declining issues outpaced advancers by a margin of nearly 7 to 5 on both the NYSE and on Nasdaq. The broader S&P 500 index slipped a point to 2,295. Bitcoin rose $14 to $1,015.
